Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17811768 | 0.83 | FFAR1 (0.41) | CA2FFAR1L3MBTL1MAPK1 | |
| SCHEMBL17815971 | 0.82 | CA2 (0.46) | CA2FFAR1GAAL3MBTL1RAB9A | |
| SCHEMBL16372327 | 0.79 | MAPK1 (0.46) | FFAR1L3MBTL1RAB9AMAPK1ALOX5 | |
| SCHEMBL16371823 | 0.79 | MTNR1A (0.42) | FFAR1L3MBTL1RAB9ALMNAMAPK1 | |
| SCHEMBL8259889 | 0.77 | CA2 (0.56) | CA2FFAR1GAAL3MBTL1RAB9A | |
| SCHEMBL8596072 | 0.76 | CA2 (0.51) | CA2GAARAB9ALMNA | |
| SCHEMBL1107090 | 0.76 | CA2 (0.51) | CA2GAARAB9ALMNA | |
| SCHEMBL8288367 | 0.76 | CA2 (0.51) | CA2GAARAB9ALMNA | |
| SCHEMBL9116625 | 0.76 | CA2 (0.55) | CA2GAARAB9ALMNA | |
| SCHEMBL1107087 | 0.76 | CA2 (0.51) | CA2GAARAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | CA2 249/4885FFAR1 898/4885GAA 2360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.